Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial

Sunwen Chou, Guy Boivin, Jane Ives, Robert Elston

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. In a large randomized trial comparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug resistance was uncommon (20 sequence variants, including the nonviable mutations and several resistance mutations.Conclusions. Newly phenotyped UL54 sequence variants did not significantly change the reported incidence of drug resistance in the clinical trial. Unrecognized sequence variants in diagnostic genotyping reports should be confirmed by additional testing in order to improve clinical decision making.

Original languageEnglish (US)
Pages (from-to)1219-1226
Number of pages8
JournalJournal of Infectious Diseases
Volume209
Issue number8
DOIs
StatePublished - Apr 15 2014

Fingerprint

DNA-Directed DNA Polymerase
Cytomegalovirus
Drug Resistance
Mutation
Ganciclovir
Organ Transplantation
Clinical Trials
Incidence
valganciclovir
Clinical Decision-Making

Keywords

  • Antiviral drug resistance
  • cytomegalovirus
  • ganciclovir
  • valganciclovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. / Chou, Sunwen; Boivin, Guy; Ives, Jane; Elston, Robert.

In: Journal of Infectious Diseases, Vol. 209, No. 8, 15.04.2014, p. 1219-1226.

Research output: Contribution to journalArticle

@article{f4470ae7069647b7931a4e4c7eb691f5,
title = "Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial",
abstract = "Background. In a large randomized trial comparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug resistance was uncommon (20 sequence variants, including the nonviable mutations and several resistance mutations.Conclusions. Newly phenotyped UL54 sequence variants did not significantly change the reported incidence of drug resistance in the clinical trial. Unrecognized sequence variants in diagnostic genotyping reports should be confirmed by additional testing in order to improve clinical decision making.",
keywords = "Antiviral drug resistance, cytomegalovirus, ganciclovir, valganciclovir",
author = "Sunwen Chou and Guy Boivin and Jane Ives and Robert Elston",
year = "2014",
month = "4",
day = "15",
doi = "10.1093/infdis/jit654",
language = "English (US)",
volume = "209",
pages = "1219--1226",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial

AU - Chou, Sunwen

AU - Boivin, Guy

AU - Ives, Jane

AU - Elston, Robert

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Background. In a large randomized trial comparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug resistance was uncommon (20 sequence variants, including the nonviable mutations and several resistance mutations.Conclusions. Newly phenotyped UL54 sequence variants did not significantly change the reported incidence of drug resistance in the clinical trial. Unrecognized sequence variants in diagnostic genotyping reports should be confirmed by additional testing in order to improve clinical decision making.

AB - Background. In a large randomized trial comparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug resistance was uncommon (20 sequence variants, including the nonviable mutations and several resistance mutations.Conclusions. Newly phenotyped UL54 sequence variants did not significantly change the reported incidence of drug resistance in the clinical trial. Unrecognized sequence variants in diagnostic genotyping reports should be confirmed by additional testing in order to improve clinical decision making.

KW - Antiviral drug resistance

KW - cytomegalovirus

KW - ganciclovir

KW - valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=84897438996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897438996&partnerID=8YFLogxK

U2 - 10.1093/infdis/jit654

DO - 10.1093/infdis/jit654

M3 - Article

VL - 209

SP - 1219

EP - 1226

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -